Dianthus Therapeutics, Inc. – NASDAQ:DNTH

Add to watchlist

$22.74

Market closed

Open in about 4 hours

-21.45%

month

-21.45%

quarter

+106.73%

year

Market Cap	690.64M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-5.89

Revenue	N/A
EBITDA	-51.89M
Income	-42.35M
Revenue Q/Q	83.61%
Revenue Y/Y	-20.14%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Dianthus Therapeutics Stock Forecast

M Q Y

Last Year

$52

Potential upside: 128.67%

Analysts Price target
Financials & Ratios estimates

Dianthus Therapeutics, Inc. (NASDAQ:DNTH): Profit margin
Jun 2023	0	-3.28M
Sep 2023	924K	-14.76M	-1597.73%
Dec 2023	457K	-10.56M	-2311.38%
Mar 2024	874K	-13.74M	-1573%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH): Debt to assets
Jun 2023	78638000	4.03M	5.13%
Sep 2023	192462000	14.08M	7.32%
Dec 2023	179405000	10.53M	5.87%
Mar 2024	382462000	9.77M	2.56%

Dianthus Therapeutics, Inc. (NASDAQ:DNTH): Cash Flow
Jun 2023	-6.54M	18.87M	0
Sep 2023	1.49M	-16.88M	154.07M
Dec 2023	-11.85M	-8.23M	-4.86M
Mar 2024	-14.94M	-5.50M	217.84M

Dianthus Therapeutics alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Dianthus Therapeutics
Employees

Dianthus Therapeutics, Inc. (NASDAQ:DNTH): Employee count
Dec 2023	32
Jan 2024	32
Feb 2024	32
Mar 2024	53
Apr 2024	53
May 2024	53
Jun 2024	53
Jul 2024	53

Dianthus Therapeutics
Latest News

Thursday, 7 November 2024
18:36	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates	zacks.com
16:01	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results	globenewswire.com
Monday, 4 November 2024
07:00	Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences	globenewswire.com
Tuesday, 15 October 2024
07:00	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting	globenewswire.com
Wednesday, 9 October 2024
04:50	Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?	zacks.com
Thursday, 8 August 2024
18:25	Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates	zacks.com
16:01	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results	globenewswire.com
Monday, 8 July 2024
12:11	Dianthus (DNTH) Gains 18% in the Past Month: Here's Why	zacks.com
Friday, 28 June 2024
11:30	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)	globenewswire.com
Wednesday, 12 June 2024
07:00	Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)	globenewswire.com
Thursday, 30 May 2024
16:30	Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference	globenewswire.com
Monday, 20 May 2024
01:38	Research Analysts Offer Predictions for Dianthus Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:DNTH)	https://www.defenseworld.net
Thursday, 9 May 2024
16:01	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results	globenewswire.com
Wednesday, 8 May 2024
16:30	Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference	globenewswire.com
Friday, 3 May 2024
16:30	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Thursday, 11 April 2024
07:30	Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting	globenewswire.com
Friday, 5 April 2024
16:30	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	globenewswire.com
Tuesday, 26 March 2024
10:46	Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks	Zacks Investment Research

Frequently Asked Questions (FAQ)

What's the price of Dianthus Therapeutics stock today?

One share of Dianthus Therapeutics stock can currently be purchased for approximately $22.74.
When is Dianthus Therapeutics's next earnings date?

Unfortunately, Dianthus Therapeutics's (DNTH) next earnings date is currently unknown.
Does Dianthus Therapeutics pay dividends?

No, Dianthus Therapeutics does not pay dividends.
How much money does Dianthus Therapeutics make?

Dianthus Therapeutics has a market capitalization of 690.64M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 55.96% to 2.83M US dollars.
What is Dianthus Therapeutics's stock symbol?

Dianthus Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "DNTH".
What is Dianthus Therapeutics's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Dianthus Therapeutics?

Shares of Dianthus Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Dianthus Therapeutics have?

As Jul 2024, Dianthus Therapeutics employs 53 workers.
When Dianthus Therapeutics went public?

Dianthus Therapeutics, Inc. is publicly traded company for more then 7 years since IPO on 21 Jun 2018.
What is Dianthus Therapeutics's official website?

The official website for Dianthus Therapeutics is dianthustx.com.
Where are Dianthus Therapeutics's headquarters?

Dianthus Therapeutics is headquartered at 7 Times Square, New York, NY.
How can i contact Dianthus Therapeutics?

Dianthus Therapeutics's mailing address is 7 Times Square, New York, NY and company can be reached via phone at +92 99994055.
What is Dianthus Therapeutics stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Dianthus Therapeutics in the last 12 months, the avarage price target is $52. The average price target represents a 128.67% change from the last price of $22.74.

Dianthus Therapeutics, Inc.

dianthustx.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

+92 99994055

7 Times Square
New York, NY 10036

CIK: 0001690585
ISIN: US2528281080
CUSIP: 252828108